natgillin/translations-raw huggingface dataset:
The recombinant RSV antigen of any one of paragraphs 3-9 and wherein the F1 domain comprises at least a portion of an RSV F protein polypeptide corresponding to amino acids 137-516 of the reference F protein precursor polypeptide (Fo) of SEQ ID NO:2. 
Rekombinantni RSV antigen u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što domena F, sadrži u najmanju ruku dio RSV F proteinskog polipeptida koji odgovara aminokiselinama 137-516 u referentnom F proteinskom polipeptidu preteči (Fo) sa SEQ ID NO:2.
The use of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or one or more pharmaceutically acceptable salts thereof for the preparation of a medicament for use on a continuous basis in the treatment of IBS-D. 
Uporaba N-metil-N-[(11S)-fenil-2-((3S)-3-hidroksipirolidin-1-il)etil]-2,2-difenilacetamida i/ili jedne ili više njegovih farmaceutski prihvatljivih soli za pripremu lijeka za neprekinutu primjenu u liječenju IBS-D-a.
The reaction mixture was stirred at room temperature for 3 hours, diluted with EtOAc, and washed sequentially with 1 N HCl, H2O, sat'd aq. NaHCO3 and brine. 
Reakcijsku smjesu miješa se 3 sata na sobnoj temperaturi, razrijedi s EtOAc, te uzastopno ispere s 1 N HCI, HO, zasićenom vodenom otopinom NaHCO,, te slanom vodom.
“Substituted C5-6 cycloalkyl” means cyclopentyl or cyclohexyl, substituted with 1 or 2, especially 1, groups selected from halo, hydroxy, methyl, trifluoromethyl, and methoxy, especially F, Cl, or methyl. 
Prefcriranc supstituiranc C5-6 cikloalkilne skupinc su ciklopentil i ciklohcksil, supstituirane sa 1 ili 2, posebno 1, skupinama odabranim od halo, hidroksi, metil, triflorometil, i metoksi, posebno floro, kloro ili metil.
In cases in which forming a socket on the end 20 of the pipe 2 involves the use of a forming chamber 1 according to any of its embodiments, the above-mentioned sub-step of enriching the process air with pressurised nebulised water is activated at the end of the socket forming time and only during the time for cooling the material of the end 20 of the pipe 2 . 
Postupak oblikovanja prema bilo kojem od zahtjeva od 14 do 16, naznačen time da korak obrade zraka za postupak sadrži, na kraju vremena oblikovanja čahure i samo tijekom vremena za hlađenje završetka (20) cijevi (2), a nakon pod-koraka hlađenja, aktivaciju pod-koraka obogaćivanja zraka za postupak sa raspršenom vodom u obliku magle pod tlakom koji se nadalje sastoji od slijedećih koraka:
10 shows the discharge device 1 in the second position, i.e., during discharge of fluid 4 . 
Slika 10 pokazuje napravu za pražnjenje 1 u drugom položaju, tj. tijekom pražnjenja tekućine 4.
an imidazolyl group optionally substituted by C1-6 alkyl group(s), 
(5) imidazolil-skupina opcijski supstituirana s jednom ili više Ci. alkil-skupina,
A host cell transformed with at least one polynucleotide sequence of claim 6, and/or the vector of claim 7, optionally wherein said host cell is E. coli. 
Stanica domaćin transformirana s najmanje jednom polinukleotidnom sekvencom iz patentnog zahtjeva 5, i/ili vektor iz patentnog zahtjeva 6, opcionalno naznačena time da je spomenuta stanica domaćin E. coli.
Meter according to claim 7, wherein the control circuit (CC) is arranged to disconnect auxiliary circuits (RFT) from the switch mode power supply (PS) in response to a change in the electric signal from the detector coil (C). 
Mjerač prema zahtjevu 6, gdje kontrolni krug (CC) isključuje pomoćne krugove (RFT) iz prekidača izvora energije (PS) kao odgovor na promjenu električnog signala iz zavojnice detektora (C).
To prepare compounds in which R3 is C1-C4 alkyl, ―COOCH2CCI3 can be used as the amino-protecting group. 
Za pravljenje spojeva u kojima je R* C;-Cx alkil, -COOCH>CCI; može se koristili kao amino-zaštitna grupa.
A powder according to claim 20 wherein the corticosteroid is selected from the group of budesonide and its epimers, beclometasone dipropionate, mometasone furoate, flunisolide, ciclesonide, rofleponide, fluticasone propionate and triamcinolone acetonide. 
Praškasta formulacija prema patentnom zahtjevu 9, naznačeno time da je kortikosteroid odabran iz skupine od budezonida i njegovih epimera, beklometazon-dipropionata, mometazon-furoata, flunizolida, ciklezonida, rofleponida, flutikazon-propionata te triamcinolon-acetonida.
A compound or pharmaceutically acceptable salt thereof, according to clause 1 or 2, wherein the compound is according to Formula IIa or IIb: 
Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time što je spoj odabran iz skupa koji sadrži:
It further includes an upward facing central cusp 214 and, below said cusp, i.e. 
Ista također sadrži središnje izbočenje 214, pruža se prema gore, a, ispod navedenog izbočenja, tj.
The method of any one of claims 1 to 3, wherein the counts in (a) and/or (b)(2) are normalized counts and wherein the normalized counts have reduced guanine-cytosine (GC) bias with respect to raw counts. 
Postupak u skladu s bilo kojim patentnim zahtjevom 1 do 3, naznačen time, da su zbrojevi u (a) i /ili (b) (2) normalizirani i pri čemu normalizirani brojevi imaju smanjenu sistemsku grešku gvanin-citozin (GC) u odnosu na neobrađene podatke.
The pharmaceutical composition of claim 8, wherein the composition is non-enteric-coated, or wherein the composition is a tablet or a capsule; or wherein the composition further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate, or wherein the composition further comprises a permeation enhancer. 
Farmaceutski pripravak za upotrebu prema zahtjevu 5, naznačen time što pripravak nadalje sadrži pomoću tvar odabranu od manitola, mikrokristalne celuloze, krospovidona, i magnezijevog stearata, ili pri čemu pripravak nadalje sadrži pojačivač permeabilnosti.
The method of claim 21 further comprising administering an additional therapeutic agent selected from an anti-inflammatory agent, an immunomodulatory agent, chemotherapeutic agent, an apoptosis-enhancer, a neurotropic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disorders. A kit for treating a condition mediated by Bruton's tyrosine kinase, comprising: a pharmaceutical composition of claim 18; and 
Farmaceutski pripravak za uporabu prema zahtjevu 22, naznačen time, da nadalje obuhvaća primjenu dodatnog terapeutskog sredstva odabranog od sljedećih: protuupalno sredstvo, imunomodulacijsko sredstvo, kemoterapeutsko sredstvo, pojačivač apoptoze, neurotropijski faktor, sredstvo za liječenje kardiovaskularne bolesti, sredstvo za liječenje bolesti jetre, antivirusno sredstvo, sredstvo za liječenje poremećaja u krvi, sredstvo za liječenje dijabetesa i sredstvo za liječenje poremećaja imunodeficijencije.
The pharmaceutical composition according to claim 3, wherein the one or more one additional therapeutic agents is an anti-HIV agent. 
Farmaceutski sastav prema zahtjevu 5 ili zahtjevu 6, pri čemu dodatno terapeutsko sredstvo ili sredstva su anti-HIV sredstva.
The mixture was redissolved in ethyl acetate (100 mL) and washed with saturated sodium hydrogen carbonate (20 mL), dried over anhydrous MgSO4 and evaporated in vacuo. 
Smjesa je opet rastopljena u etil acetatu (100 mL) i oprana zasićenim sodij hidrogen karbonatom (20 mL), te osušena nad anhidridnim i MgSO, evaporirana in vacuo.
1) comprises a first heat exchanger 50, located on the process air feed line 3 upstream of the evaporator 40 relative to the forming chamber 1 along the process air path from the compressed air source 30 to the forming chamber 1 . 
(30) uzduž puta zraka za postupak od izvora komprimiranog zraka (30) do komore za oblikovanje (1) i namijenjen je za skupljanje kondenzirane vlage u zraku za postupak koja izlazi iz isparivača (40).
Template device, as claimed in claim 1, characterized in that a roll (13) makes sliding of the slab easier during slab feeding on a conveyor belt. 
Stroj za poliranje prema prethodnim zahtjevima, naznačen time, da postoji valjak (13) koji olakšava klizanje ploče prilikom ulaženja ploče na transportnu traku.
An attempt to produce an aqueous solution of roflumilast, e.g. for injection, does not, despite addition of the solubilizer poloxamer 188 which is normally employed in connection with parenteral preparations, result in a solution having a roflumilast concentration which is acceptable for injections. 
Pokušaj da se pripremi vodena otopina roflumilasta, na primjer za injekcije, nije rezultirao otopinom koja bi imala koncentraciju roflumilasta prihvatljivu za injekcije usprkos dodavanju solubilizatora poloksamera 188 koji se normalno koristi skupa s parenteralnim preparatima.
A process for preparing a compound of the formula VII 
Postupak dobivanja spoja formule VII gdje
The pharmaceutical composition of claim 19, wherein said further therapeutic agent is an anti-angiogenic agent or a chemotherapeutic agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 26, naznačen time što navedeno dodatno terapijsko sredstvo je antiangiogeno sredstvo ili kemoterapijsko sredstvo.
wherein the crushing blade (510) crushes the material within the crushing processing portion formed in the bottom of the lid, in advance of the material reaching the sieve (200). 
Modul za ekstrakciju soka u skladu s patentnim zahtjevom 1, naznačen time što donji kraj površine za vođenje materijala (620) odgovara unutarnjoj površini sita (200).
Usually such beverage containers 2 are not blown to their full size until immediately before their filling with beverage. 
Takovi spremnici za pića 2 se obično ne napuhuju do njihove potpune veličine sve do neposredno prije njihovog punjenja s pićem.
An antibody or antigen-binding portion thereof according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 9 for use in a method for treating cancer in a mammal, the method comprising administering the antibody or antigen-binding portion thereof or the pharmaceutical composition to said mammal. The antibody or antigen-binding portion thereof or the pharmaceutical composition according to claim 10 for the use according to claim 10, wherein the mammal is human patient. 
Antitijelo ili njegov dio koji se veže na antigen sukladno bilo kojem od zahtjeva 1 do 9 ili farmaceutski pripravak sukladno zahtjevu 10, naznačen time, da se upotrebljava u postupku za liječenje raka kod sisavca, postupak obuhvaća primjenu antitijela ili dijela koji veže antigen. 1li njegovog farmaceutskog pripravka navedenom sisavcu. Antitijelo ili njegov dio koji se veže za antigen ili farmaceutski pripravak sukladno zahtjevu 11 za uporabu sukladno zahtjevu 11, naznačen time, što je sisavac ljudski pacijent.
wherein said hydroxy-containing polymer is a combination of polyvinyl alcohol and at least one member selected from the group consisting of starch, modified starch and a sugar, wherein said polyvinyl alcohol has a viscosity up to 10 centipoise when in a 4% aqueous solution at 20° C. The method for preparing the nonwoven material of claim 21, further comprising a step of diluting the curable aqueous composition with sufficient water so the curable aqueous composition has 95% by weight of water prior to the heating step. 
HR P20141042 T1 pri čemu je spomenuti hidroksi-polimer kombinacija polivinil-alkohola i najmanje jednog koji je izdvojen iz grupe, koji se sastoji od škroba, modificiranog škroba 1 šećera. Postupak priprave netkanih materijala iz zahtjeva 18, naznačen time, da dalje obuhvaća korak razrjeđivanja učvršćujućeg vodenastog pripravka sa dovoljno vode, tako da učvršćujući vodenasti pripravak ima 95% težine vode, prije koraka zagrijavanja.
The combination for use of Claim 4 or Claim 5, wherein the B-lactamase inhibitor is in the form of a sodium salt. 
Kombinacija za uporabu sukladno patentnom zahtjevu 4 ili patentnom zahtjevu 5, naznačena time što je inhibitor B-laktamaze u obliku natrijeve soli.
The rim of one of the preceding claims, wherein the internal portion (22) is made of a metal material. 
Obruč prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je unutarnji dio (22) napravljen od metalnog materijala.
The compound according to claim 1, which is 2-{[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxy}-4-methylpentan-1-amine, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time da je 2-([3-(1-benzofuran-2-il)imidazol[1,2-b]piridazin-6-illoksi!)-4- metilpentan-1-amin, ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, naročito njegova farmaceutski prihvatljiva sol.
Separately there was prepared an aqueous solution containing a surfactant (sodium dodecylbenzenesulphonate 0.5%) and a catalyst (phosphoric acid 1.6%). 
Posebno pripremimo vodenu otopinu, koja sadrži površinski aktivnu tvar (natrijev dodecilbenzensulfonat) 0,5 % 1 katalizator (fosforovu kiselinu, 1,6 %).
A process for preparing a compound of formula (IV) is illustrated in Scheme 1. wherein: 
2. 20 Postupak dobivanja spoja formule (IV): pri čemu:
Use of phospholipids in combination with an active principle according to claim 10, to be administered orally for the treatment of gastrointestinal irritation disorders and to synergistically improve its antiulcer activity. 
Uporaba prema zahtjevu 11, gdje je ta smjesa namijenjena oralnoj primjeni za liječenje iritabilnih probavnih poremećaja 1 za sinergijsko poboljšanje učinka sukralfata protiv čira.
A Combination therapeutic means, in particular a combination product, comprising as active ingredients: 
Kombinirana terapeutska sredstva, naročito kombinirani proizvod, koji sadrži kao aktivne sastojke:
Figure 12 is a plan view of the sheet metal strip on termination of the pressing stage, 
je pogled s gornje strane na limenu metalnu traku na završetku faze prešanja, slika 14
The method for producing a nicotine-containing granulate according to claim 1, wherein prior to the mixing in step (a), sweeteners, binding agents, separating agents, lubricants, coloring agents, flavor additives, acids, effervescent agents, antioxidants, glidants and/or preservatives are added. 
Postupak dobivanja granulata koji sadrži nikotin u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time što se sladila, veziva, sredstva za razdvajanje, maziva, bojila, arome, kiseline, pjenila, antioksidante, sredstva za kliženje i/ili konzervanse pomiješa s drugim komponentama u koraku (a).
wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the plant, and wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on weight of the extract, wherein extracts comprising a), b), and c) are obtainable from a plant comprising the inflorescence of any one of claims 1-10. 
gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, a-felandrena, B-ocimena, karena, limonena, Y-terpinena, a-pinena, a-terpinena, B-pinena, fenhola, kamfena, a-terpineola, a-humulena, B-kariofilena, linaloola, kariofilen-oksida, te mircena of the biljka, te gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi težine ekstrakta, gdje se ekstrakte koji sadrže a), b), c), te d) može dobiti iz biljke koja sadrži inflorescenciju u skladu s patentnim zahtjevom 1.
Accordingly, in a first aspect, the invention provides 3, 11b -cis- dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease, and more particularly a symptom selected from involuntary movements such as involuntary chorea, tremors and twitches, and degeneration in gait. 
Prema tome, u prvom aspektu, izum osigurava spoj za uporabu u zaustavljanju ili usporavanju napretka jednog ili više simptoma Huntington-ove bolesti kod pacijenta gdje su simptomi izabrani između nenamjernih pokreta i pogoršanja hoda, pri čemu je spoj (+) izomer 3,1 1b-cis-dihidrotetrabenazina ili njegova farmaceutski prihvatljiva sol.
a variant of amino acid residues 20 to 139 of SEQ ID NO: 30, wherein said variant comprises one, two or three conservatively modified amino acid substitutions; or 
aminokiselinski ostaci 20 do 139 iz sekv. id. br.: 30 ili njene varijante, pri čemu navedena varijanta sadrži jednu, dvije ili tri konzervativno modificirane aminokiselinske supstitucije; i
The filling medium should then be insoluble or very difficultly soluble in water. 
Punilo, zatim, mora biti netopivo ili vrlo teško topivo u vodi.
Typically, composite materials have a distribution of one or more sizes of fine particles plus microfine and/or nano-size filler (5-15%). 
Tipično, kompozitni materijali imaju distribuciju jedne ili više veličina finih čestica plus mikrofine i/ili punila nano-veličina (5-15%).
from 0.1% to 2% by weight on a dry weight basis of magnesium stearate; 
od 0,1 do 2 masena postotka na bazi suhe mase magnezijevog stearata;
Particularly preferably said halogen is fluoro. 
Naročito poželjan spomenuti halogen je fluor.
Methods for converting substituents into other substituents are known in the art. 
Postupci za konverziju jednih supstituenata u druge poznati su u struci.
In a second aspect the invention provides a method for the quantification of a virulent strain of Marek's Disease Virus Serotype-1 (MDV-1) in a sample from a bird, comprising the steps of: 
Postupak kvantificiranja virulentnog soja virusa Marekove bolesti serotip-1 (MDV-1) u uzorku iz ptice, naznačen time što se sastoji u koracima:
Administration of a reversible, short-acting P2Y12 inhibitor can be made several days to several hours prior to the invasive procedure. 
Reverzibilni, kratko djelujući inhibitor P2Y,, za uporabu u postupku prema bilo kojem od zahtjeva 4 do 7, naznačen time da invazivni postupak je perkutana koronarna intervencija.
Embodiment No. 11: In a further embodiment of the present invention the process described in embodiments no. 8 to 10 further incorporate an anti oxidants selected from a group comprising Butylated Hydroxy Anisole, Butylated Hydroxy Toluene and the like from about 0.001% (w/w) to 5% (w/w), preferably 0.1% (w/w), more preferably 0.01% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 9 do 12, naznačen time, da se nadalje antioksidans dodaje u stupnju h patentnog zahtjeva 9, kod čega se navedeni antioksidans odabire iz skupine koja sadrži butilirani hidroksianisol, butilirani hidroksitoluen i slične, od oko 0,001% (tež.) do 5% (tež.), prvenstveno 0,1% (tež.), pogodnije 0,01% (tež.).
A winch according to any one of claims 1 to 9 wherein the self-tailing arrangement includes a reverse wind rope extractor extending into the rope guide channel in a direction opposite to the reverse wind direction. 
Vitlo prema bilo kojem od zahtjeva 1 do 8, naznačeno time, da uređaj za samopovlačenje uključuje povratni ekstraktor za namatanje užeta (276), koji se proteže u žlijebu za vođenje užeta u suprotnom smjeru od smjera povratnog namatanja.
As shown in Figure 32, the ester compound of Formula 27 is next saponified to its corresponding carboxylic acid of Formula 28 (where R2=CH2CH(CH3)2; P3=CBZ; R11=H; R12=PhOMe in generalized formula V of Scheme 8). 
Kao stoje prikazano na slici 32, spoj cstera formule 27 sc sljedeći saponificira u svoju odgovarajući karboksilnu kiselinu formule 28 (gdje R>=CH2CH(CH;),; P3=CBZ; R,,=H; R;»=PhOMe u općoj formuli V iz sheme 8).
A single-chain antibody, comprising a VH, a VL and a linker peptide, wherein the VH has a sequence as set forth in SEQ ID NO.4, the VL has a sequence as set forth in SEQ ID NO.9, and the linker peptide has a sequence as set forth in SEQ ID NO.1. 
Jednolančano antitijelo, koje sadrži VH, VL i vezujući peptid, pri čemu VH ima sekvencu kako je navedeno u SEQ ID NO.4, VL ima sekvencu kako je navedeno u SEQ ID NO.9, i vezujući peptid ima sekvencu kako je navedeno u SEQ ID NO.1.
Preferred flow rate ratios include from at least 20:1 up to 1000:1; from at least 20:1 up to 800:1; from at least 20:1 up to 600:1. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu je udio protoka drugog tekućeg mlaza: prvi tekući mlaz najmanje 20:1 do 1000:1.
Clinical forms of the disease are greatly varied, most of the cases are of the relapsing-remitting type, all the same. 
Klinički simptomi bolesti su raznoliki, u većini slučajeva radi se o relapsirajuće-remitirajućem obliku (pogoršanje-poboljšanje).
The method of claim 5, wherein the unscheduled media item is selected for output in said program slot according to one or more constraints associated with one or more media items for output in at least one other slot. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se neraspoređenu medijsku točku bira za izlaženje u navedenoj rupi prema jednom ili više ograničenja povezanih s jednom ili više medijskih točaka na rasporedu za izlaženje u najmanje jednoj drugoj rupi u programu.
The compound according to claim 10 for treating chronic obstructive pulmonary disease. 
Spoj u skladu s patentnim zahtjevom 10, naznačen time što je namijenjen liječenju kronične opstruktivne plućne bolesti.
As much as possible of the aerosol former carried on the aerosol generating means should be delivered to the user as WTPM. 
Å to je moguće više formirača aerosola koji sadrži sredstvo za generiranje aerosola treba da se provede korisniku kao WTPM.
Completely foreign impurities, of environmental origin, but always present, particularly in fish oils and in all their transformation derivatives, are represented by several toxins, as aflatoxin, hydrocarbons as benzopyrene, pesticides as DDT, industrial agents as PCB and dioxin (McEwen FL, Stephenson GR, The use and significance of pesticides in the environment, Chapter 15. 
Potpuno strana onečišćenja, porijeklom iz okoliša, ali uvijek prisutna, naročito u ribljim uljima i u svim njihovim transformacijskim derivatima, su predstavljena s nekoliko toksina, kao što je aflatoksin, ugljikovodici kao benzopiren, pesticidi kao DDT, industrijski agensi kao PCB i dioksin (McEwen FL, Stephenson GR, The use and significance of pesticides in the environment, Chapter 15.
The tetrabenazine used as the starting material for the reduction to give the dihydrotetrabenazine can be obtained commercially or can be synthesised by the method described in US 2,830,993 (Hoffmann-La Roche). 
Tetrabenazin koji se koristi kao polazni materijal za redukciju da bi se dobio dihidrotetrabenazin, se može nabaviti komercijalno ili se može sintetizirati postupkom opisanim u US 2,830,993 (Hoffmann-La Roche).
wherein each R10 and R11 is independently absent, hydrogen, halogen, aliphatic, substituted aliphatic, aryl or substituted aryl; 
svako R20 i R21 je nezavisno izabrano od vodika, alifatika, supstituiranog alifatika, arila ili supstituiranog arila;
Furthermore, it has surprisingly been found that the surface-treated calcium carbonate material obtained by the process according to the present invention may advantageously be used for controlling organic material in an aqueous medium. 
Postupak za kontrolu organskog materijala u vodenom mediju, naznačen time da se u medij dodaje materijal od površinski obrađenog kalcijevog karbonata ili vodena suspenzija koja sadrži materijal površinski obrađenog kalcijevog karbonata prema zahtjevu 19 ili 20.